Aisa Pharma Reports Positive Results for AISA-021

Why It Matters

The results suggest AISA‑021 could become the first approved therapy for SSc‑related Raynaud’s, addressing a high‑unmet‑need and potentially reshaping the treatment landscape.

Key Takeaways

• Phase II trial enrolled 64 systemic sclerosis patients.
• 22.1% reduction in Raynaud attacks vs baseline.
• Attack‑free days increased 155% placebo‑adjusted.
• Significant improvements in attack duration and skin temperature.
• No treatment‑related serious adverse events reported.

Pulse Analysis

Systemic sclerosis‑associated Raynaud’s phenomenon remains one of the most debilitating complications of scleroderma, with patients experiencing frequent, painful vasospastic attacks that impair daily function. Existing calcium channel blockers offer modest relief, and no therapy has secured regulatory approval specifically for this indication. Aisa Pharma’s AISA‑021, a novel cilnidipine formulation, aims to fill this gap by targeting both L‑ and N‑type calcium channels, potentially delivering superior vasodilatory control and symptom mitigation.

The RECONNOITER Phase II study employed a rigorous double‑blind, crossover design, enrolling 64 participants across two dosing arms (10 mg and 20 mg) and evaluating co‑administration with PDE‑5 inhibitors. Although the primary endpoint—a reduction in weekly Raynaud attacks—did not achieve statistical significance, the trial revealed a 22.1% drop from baseline and a striking 155% placebo‑adjusted rise in attack‑free days, alongside shorter attack duration and improved distal skin temperature. Patient‑reported outcomes via the SHAQ PRO instrument also trended positively for pain, gastrointestinal function, and overall disease burden, reinforcing the drug’s multi‑dimensional benefit profile.

These findings position AISA‑021 as a compelling candidate for Phase III development, where larger sample sizes could confirm efficacy and satisfy regulatory thresholds. Successful registration would not only provide the first disease‑specific therapy for SSc‑related Raynaud’s but also open a new market segment for calcium channel blockers in rare autoimmune disorders. Investors and clinicians alike will watch Aisa Pharma’s upcoming FDA engagement closely, as the company seeks to translate Phase II promise into a commercial reality that could improve quality of life for thousands of patients worldwide.